Peptide Guides
Important
BPC-157 is not an approved medicine in any country. It holds no licence from the MHRA in the United Kingdom, the EMA in Europe, or the FDA in the United States. This guide summarises the published research on safety. It is not medical advice, and nothing within it constitutes a recommendation to use BPC-157. Products supplied through this site are intended for laboratory research use only.
Quick answer
- No true side-effect profile for BPC-157 exists, because the controlled human studies that produce one have never been run.
- Animal studies report no toxicity signal, and three small human reports covering thirty people noted no adverse events.
- Thirty people in uncontrolled reports cannot establish safety, and those reports were not designed to detect harm.
- Unknown is not the same as safe, and it is not the same as dangerous. It is unknown.
What is known about BPC-157 side effects
A side-effect profile is the reliable list of what a compound does to people and how often each effect occurs. It comes from controlled human trials that record every adverse event across hundreds or thousands of participants, and from monitoring after a medicine reaches the market. BPC-157 has had none of that. Not one controlled human trial has been published.1,2
The published evidence on BPC-157 safety consists of animal studies, three small human reports, and reviews of both. (Our full guide to BPC-157 covers the compound itself, including what it is, where it came from, and the shape of its research record.)
Why no side-effect profile exists
A reaction affecting one person in a hundred needs hundreds of monitored participants to show up reliably. A reaction affecting one in a thousand needs thousands. Rare but serious effects, the kind that change a medicine's fate, are routinely invisible in small studies and only surface in large trials or after a medicine reaches the market.
The entire published human experience with BPC-157 is thirty people.3,4,5 Even if every one of them reported honestly and was followed carefully, thirty people could only reveal side effects so common that most users would experience them. Anything rarer is undetectable at that scale. Our guide to reading a peptide study covers this in more depth.
What animal studies report
The animal record on BPC-157 toxicity is unusually clean. Studies in rats and mice, including decades of work from the compound's discoverers, report no lethal dose established and no consistent toxicity signal.2,6
Most of the work comes from a single research group, so independent confirmation is thinner than the paper count suggests. Animal studies measure what their designers look for, and systematic toxicology of the kind regulators require, covering organ function, reproduction, development and cancer risk over long periods, has not been published for BPC-157. Clean animal results also do not transfer automatically to people, in either direction. Our guide to animal versus human peptide research explains why.
What the human reports can and cannot show
Three human reports exist, all from one private clinic in Florida; the human trials of BPC-157 are catalogued in full in our Research Library. A 2021 report contacted 16 knee-pain patients by phone and reported no complaints.3 A 2024 report on 12 women treated for bladder pain reported no adverse events.4 A 2025 report gave intravenous BPC-157 to 2 people and found no changes in blood markers for the heart, liver, kidneys or thyroid.5
Reviews of this literature note the same two things. No major adverse effects have been reported, and the human research is too limited to conclude anything from that.2 A 2026 primer for orthopaedic surgeons described the human evidence as carrying significant methodological flaws and lacking controls.1
None of these reports was designed to detect harm. There was no comparison group, no systematic recording of adverse events, and follow-up that relied partly on what patients recalled by phone. Reports like this can show that nothing dramatic happened to thirty people. They cannot show that a compound is safe.
BPC-157, cancer and blood vessel growth
The cancer concern has a specific, rational origin. In animal and cell studies, BPC-157 promotes angiogenesis, the growth of new blood vessels.2 Healing tissue needs new blood vessels. So do tumours, which cannot grow beyond a few millimetres without recruiting a blood supply. A compound that encourages blood vessel growth therefore raises a reasonable theoretical question. Could it help an existing tumour grow?
Three facts cover that question. No study has shown BPC-157 causing or accelerating cancer. No study has been designed to find out, in animals over cancer-relevant timescales or in humans at all. And the theoretical concern is taken seriously enough that published reviews raise it as a reason controlled safety research is needed.1,2
A claim that BPC-157 causes cancer is unsupported. So is a claim that it has been shown safe in this respect. Neither statement has evidence behind it.
Side effects in men versus women
No study has compared BPC-157 side effects in men and women, and no study could have. The published human experience is 16 mostly unspecified knee patients, 12 women, and 2 people. Any claim about sex-specific side effects of BPC-157, in either direction, is invented.
Hormonal interactions, effects in pregnancy, and effects on fertility have never been studied in humans. For a compound with no licence, no regulator has ever required them to be.
The quality risk nobody lists as a side effect
One risk attaches to unlicensed compounds regardless of their chemistry. Nobody independent checks what a vial contains. A licensed injectable medicine is manufactured to sterility and contamination standards and tested against them. Research-grade material is not, and its actual contents depend entirely on the supplier's testing. An adverse reaction to an unregulated product may have nothing to do with the named compound and everything to do with what accompanied it.
This is the one safety variable a supplier can control, which is why each batch supplied through this site is independently tested for purity before listing, with the dated certificate of analysis published for download. A certificate does not make a compound safe. It establishes what the vial contains, which is the necessary starting point.
Common questions about BPC-157 safety
Is BPC-157 safe?
Unknown. Animal studies report no toxicity signal, thirty people in uncontrolled reports experienced no recorded adverse events, and the controlled human research that establishes safety has never been done. Whether it works is a separate question, examined in our guide to whether BPC-157 works.
Does BPC-157 cause cancer?
No study has shown that it does, and no study has been designed to find out. The concern arises because BPC-157 promotes blood vessel growth in animal studies, and tumours also depend on blood vessel growth. Published reviews treat this as an open question requiring proper research.
Are BPC-157 side effects different for men and women?
No human study has compared them, so any specific claim is unsupported. The published human experience totals thirty people and was not designed to detect differences between anyone.
Has anyone been harmed by BPC-157?
The three published human reports recorded no adverse events. Outside published research, no reporting system tracks harms from unlicensed compounds, so absence of published harm is weak evidence.
Specification and supply
The BPC-157 research peptide supplied through this site is freeze-dried (lyophilised) powder, purity-tested by HPLC, with a certificate of analysis issued per batch. The full range is listed under research peptides.
Supplied for laboratory research use only. Not for human consumption.
References
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. DOI
- Yuan C, Demers A, Silva-Ortiz V, et al. From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026. DOI
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PMID 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PMID 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PMID 40131143
- Matek D, Matek I, Japjec M, et al. Tendon, ligament, and muscle injury therapy perspectives with growth factors and stable gastric pentadecapeptide BPC 157: a review. Pharmaceuticals (Basel). 2026. DOI